Pfizer R&D Reshuffling Deals Out Pharmacia’s Investment In Sugen
Pfizer will cease investment in the biotech company Sugen as part of a reorganization of Pfizer/Pharmacia's combined R&D facilities
You may also be interested in...
Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen
Pfizer's decision about the future of the former Upjohn campus in Michigan provides an opportunity for the company to renew its push for changes to the state's Medicaid program
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger